AngioChem to Present New ANG1005 Clinical Data at AACR

MONTREAL--(BUSINESS WIRE)--Apr 7, 2009 - AngioChem, a biotechnology company discovering and developing drugs that are uniquely capable of crossing the blood-brain barrier, today announced that it will present updated data from clinical studies of ANG1005 at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 18-22, 2009 in Colorado. The data to be presented relate to the potential safety, efficacy and utility of ANG1005 in primary and secondary brain cancers.

ANG1005 is a novel taxane derivative created from the Engineered Peptide Compound (EPiC) platform that is designed to cross the blood-brain barrier (BBB) by receptor-mediated transcytosis, overcoming the BBB's normal function of blocking foreign substances which prevents more than 95 percent of all drugs from reaching the brain.

The schedule of poster presentations for ANG1005 is as follows:

Abstract Title:       ANG1005 as a promising new drug therapy for patients with malignant glioma
Poster Session:       Experimental and Molecular Therapeutics 26
Number:       3781
Date/Time:       Tuesday, April 21, 2009, 8:00 AM Local Time
Location:       Hall B-F, Poster Section 38
         
Abstract Title:       ANG1005: Development of a new chemical entity for the treatment of advanced solid tumors and brain
        metastases
Poster Session:       Experimental and Molecular Therapeutics 26
Number:       3782
Date/Time:       Tuesday, April 21, 2009, 8:00 AM Local Time
Location:       Hall B-F, Poster Section 38

Abstracts and information about the AACR and its Annual Meeting may be found at www.aacr.org.

About ANG1005

ANG1005 is a novel taxane Engineered Peptide Compound (EPiC) that is designed to cross the BBB. Studies have shown that ANG1005 gains entry into the brain compartment by targeting the low-density lipoprotein receptor-related protein (LRP) which is one of the most highly expressed receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain.

ANG1005 is currently being evaluated in two separate Phase 1/2 multicenter, open-label, dose escalation studies to explore the maximum tolerated dose and obtain data on safety, tolerability and preliminary evidence of efficacy in patients with recurrent malignant glioma, and in patients with advanced solid tumors and brain metastases. For recurrent malignant gliomas and metastatic brain cancer, treatment options for patients are limited and prognoses are dismal.

Data to date from the Phase 1/2 studies of ANG1005 in patients with primary and secondary brain cancers demonstrated that ANG1005 has an excellent safety and tolerability profile, as evidenced by laboratory and neurocognitive data, and does not show evidence of eliciting an immune response in humans.

About AngioChem

AngioChem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases. These new Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention. AngioChem's lead product candidate, ANG1005, is in two separate Phase 1/2 clinical studies in patients with primary brain cancers and in cancer metastases. Additionally, AngioChem is developing a deep and broad product pipeline, including small and large molecules, for the treatment of a wide range of brain diseases and related disorders, including brain cancer, cancer metastases, neurodegenerative and metabolic diseases. Founded in 2006, AngioChem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.

Contact: Yates Public Relations
Kathryn Morris, 845-635-9828

***

Posted: April 2009

View comments

Hide
(web4)